Drug intelligence / Profile preview

Ganmao Qingre Granules

Development stage: Unknown
Lead developer: Yunnan Yongzitang Pharmaceutical
Administration: Oral

Overview

Ganmao Qingre Granules is a traditional Chinese medicine (TCM) formulation produced by Yunnan Yongzitang, a subsidiary of Hunan Hansen Pharmaceutical. It is an approved herbal product used for the treatment of the common cold and upper respiratory tract infections, particularly those presenting with wind-cold symptoms such as headache, fever, chills, body aches, runny nose, and cough. The formulation is a complex mixture of multiple botanical ingredients, including *Schizonepeta tenuifolia*, *Mentha haplocalyx*, and *Saposhnikovia divaricata*, which work synergistically to 'release the exterior' and 'dispel wind-cold.' It is administered orally as granules dissolved in water.

Brand names: Yunnan Yongzitang Ganmao Qingre Granules
Other names: Ganmao Qingre Keli感冒清热颗粒

Beyond the preview

Go deeper on Ganmao Qingre Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ganmao Qingre Granules.

Explore the full profile